Close Menu

codevelopment agreement

The companies will develop and market PITX2 as a marker to predict effectiveness of anthracycline treatment in triple negative and other high-risk breast cancer patients.

The firms will collaborate on creating and co-marketing array technologies for research and clinical diagnostics.

Both companies are working together to market both companies' technology for long-read DNA sequencing. 

Toma Biosciences will use Seraseq biosynthetic reference material technology to develop and validate its Toma OS-Seq reagent kits. 

The diagnostic test is intended to help physicians decide if and how to use Mirati's targeted therapy in non-small cell lung cancer patients. 

The agreement calls for HTG to develop several in vitro diagnostics on Thermo Fisher's next-generation sequencing-based Ion PGM Dx system.

The partnership will pair Sophia's informatics infrastructure with IDT's panel to provide an NGS-based solution for routine clinical diagnostics.

They plan to combine Silicon’s DEPArray digital-sorting technology with Macrogen’s NGS systems to develop genomic tests for different cancers.

The companies will each create products using Agilent's SureSelect target enrichment technology on 10x's Chromium platform.

The companies plan to combine Qiagen's sample technologies with 10x's microfluidics-based linked-read sequencing systems.


Researchers tie a variant in ADAMTS3 to breathing difficulties in dissimilar dog breeds, according to Discover's D-brief blog.

The Japan Times reports that researchers sequenced the genome of a woman who lived during the Jomon period.

Parents of children with rare genetic disease have to contend with shifts in the interpretation of genetic variants, the Wall Street Journal reports.

In Science this week: single-nucleus RNA sequencing of brain tissue from individuals with autism, and more.